Vor Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	63.6	43.48	27.88	31.72	28.87	21.49
Research & Development	53.78	298.46	93.31	94.32	64.55	47.53
Operating Expenses	117.37	341.94	121.19	126.04	93.42	69.02
Operating Income	-117.37	-341.94	-121.19	-126.04	-93.42	-69.02
Interest & Investment Income	12.8	5.87	4.27	8.17	1.32	0.12
Other Non Operating Income (Expenses)	757.91	-334.36	-	-	-	-
EBT Excluding Unusual Items	653.34	-670.43	-116.91	-117.86	-92.09	-68.9
Merger & Restructuring Charges	-29.71	-29.71	-	-	-	-
Gain (Loss) on Sale of Assets	4.15	4.15	-	-	-	-
Pretax Income	627.78	-695.98	-116.91	-117.86	-92.09	-68.9
Net Income	627.78	-695.98	-116.91	-117.86	-92.09	-68.9
Preferred Dividends & Other Adjustments	-	-	-	-	-	1.23
Net Income to Common	627.78	-695.98	-116.91	-117.86	-92.09	-70.13
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	31	10	3	3	2	2
Shares Outstanding (Diluted)	31	10	3	3	2	2
Shares Change	540.03%	187.35%	2.26%	69.88%	18.30%	15547.86%
EPS (Basic)	20.19	-70.50	-34.03	-35.08	-46.57	-41.95
EPS (Diluted)	20.19	-70.50	-34.03	-35.08	-46.57	-41.95
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-140.81	-143.65	-99.89	-101.36	-93.61	-73.04
Free Cash Flow Per Share	-4.53	-14.55	-29.07	-30.17	-47.33	-43.69
EBITDA	-117.29	-339.05	-117.66	-122.54	-90.89	-67.58
D&A For EBITDA	0.09	2.89	3.53	3.49	2.53	1.43
EBIT	-117.37	-341.94	-121.19	-126.04	-93.42	-69.02

SEC Filings: 10-K · 10-Q